We believe engaging in constructive dialogue with our stakeholders, including patients, health care providers, employees, investors, communities, suppliers and partners, is critical for our long-term success.
These relationships provide us with new perspectives and valuable information that help us identify issues and improve our performance. We collect feedback on an ongoing basis through established channels in government relations, investor relations and patient services, as well as individual meetings with other organizations, as necessary.
We also belong to a number of industry organizations, which share best practices within and outside our industry. Some of these groups include:
- BioPharma EHS Forum
- Biotechnology Industry Organization
- Corporate Responsibility Officer Association (CROA)
- Direct Employers
- Global Environmental Management Initiative (GEMI)
- ORC Worldwide (ORC)
- Pharmaceutical Supply Chain Initiative (PSCI)
Specific examples of our engagement include:
Engaging with Patients
We are committed to improving and extending the lives of our patients, and we work with them and others to ensure we are meeting our patients’ needs as best we can. We provide support services to help our patients cope with the challenges associated with living with their diseases, as well as resources to assist them in obtaining free or discounted medicines. We continuously evolve our suite of services based on feedback from our patients. To learn more about our offerings, please see Patient Services.
Engaging with our Employees
Creating dialogue and listening to our employees is key to our success and also to keeping our employees engaged and satisfied. We conduct a full employee survey biannually, and we also work to solicit employee feedback through roundtables, an annual employee meeting and our compliance hotline. To learn more about our employee engagement, please see Our Culture.
Engaging with Investors
We continually engage in active discussions with our shareholders. In 2010, we invited one of our largest shareholders that has expertise in evaluating environmental, social and governance performance to attend our Sustainability Leadership Committee’s fall meeting. During this session, we discussed how we could better address its needs and the needs of its investors.